Evaluating Nausea Reporting in GLP-1 Agonist Obesity Trials | Retatrutide News

A review highlights gaps in nausea reporting in GLP-1 obesity trials, affecting drugs like Retatrutide. Accurate side effect measurement is crucial for ...
Patient Experiences · October 24, 2026